Abstracts Archive - Page 1547 of 2425 - ACR Meeting Abstracts

Abstract Number: 1945 • 2016 ACR/ARHP Annual Meeting
Development and Validation of Case-Finding Algorithms for the Identification of Patients with ANCA-Associated Vasculitis and Large-Vessel Vasculitis in Healthcare Administrative Databases
Antoine G. Sreih¹, Narender Annapureddy², Jason Springer³, Kevin Byram⁴, George Casey⁵, Andy Cruz⁶, Maya Estephan⁷, Vince Frangiosa⁸, Michael D. George⁸, Mei Liu⁹, Mehrdad Maz¹⁰, Adam Parker⁷, Sapna Sangani¹¹, Rebecca Sharim¹² and Peter A. Merkel¹³, ¹Rheumatology, The University of Pennsylvania, Philadelphia, PA, ²Vanderbilt University, Nashville, TN, ³Department of Internal Medicine, Division of Allergy, Clinical Immunology, & Rheumatology, Kansas University Medical Center, Kansas City, KS, ⁴Internal Medicine, Vanderbilt University, Nashville, TN, ⁵The Vasculitis Foundation, Kansas City, MO, ⁶Informational Technology, The University of Pennsylvania, Philadelphia, PA, ⁷Rheumatology, The University of Kansas, Kansas City, KS, ⁸Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Informational Technology, The University of Kansas, Kansas City, KS, ¹⁰Allergy, Clinical Immunology, and Rheumatology, The University of Kansas Medical Center, Department of Internal Medicine, Division of Allergy, Clinical Immunology and Rheumatology, Kansas City, KS, ¹¹Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Temple University, Philadelphia, PA, ¹³Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of vasculitides that consists of granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA), and microscopic polyangiitis…
Abstract Number: 1946 • 2016 ACR/ARHP Annual Meeting
Antineutrophil Cytoplasmic Antibody (ANCA) Type and Body Mass Index in ANCA-Associated Vasculitis (AAV)
Zachary Wallace¹, Na Lu², Eli Miloslavsky³, Ulrich Specks⁴, Gary S. Hoffman⁵, Cees G.M. Kallenberg⁶, Carol A. Langford⁷, Peter A. Merkel⁸, Paul A. Monach⁹, Philip Seo¹⁰, Robert F. Spiera¹¹, Eugene William St.Clair¹², Paul Bruntetta¹³, Hyon K. Choi¹⁴ and John H. Stone¹⁵, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Mayo Clinic, Rochester, MN, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Medicine, Johns Hopkins University, Baltimore, MD, ¹¹Hospital for Special Surgery, Cornell, New York, NY, ¹²Rheumatology and Immunology, Duke University, Durham, NC, ¹³Genentech, Inc., South San Francisco, CA, ¹⁴Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, ¹⁵Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Antineutrophil Cytoplasmic Antibody (ANCA) Type and Body Mass Index in ANCA-Associated Vasculitis (AAV) Background/Purpose: Phenotypic, genetic, and treatment differences distinguish PR3- and MPO-ANCA+ ANCA-associated vasculitis…
Abstract Number: 1947 • 2016 ACR/ARHP Annual Meeting
Ocular Manifestations of ANCA-Associated Vasculitis
Sophie Cai^1,2, George Papaliodis^2,3, Leo Lu⁴, Hyon K. Choi⁵, Ulrich Specks⁶, Peter A. Merkel⁷, Philip Seo⁸, Robert F. Spiera⁹, Carol A. Langford¹⁰, Gary S. Hoffman¹¹, Cees G.M. Kallenberg¹², William St Clair¹³, Nadia Tchao¹⁴, Fernando Fervenza⁶, Paul A. Monach¹⁵, W Joseph McCune¹⁶, John H. Stone¹⁷, Eli Miloslavsky¹⁸ and RAVE-ITN and WGET Research Groups, ¹Ophthalmology, Johns Hopkins Wilmer Eye Institute, Baltimore, MD, ²Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Uveitis and Immunology, Massachusetts Eye and Ear, Boston, MA, ⁴Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Mayo Clinic, Rochester, MN, ⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁸Medicine, Johns Hopkins University, Baltimore, MD, ⁹Hospital for Special Surgery, Cornell, New York, NY, ¹⁰Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatology, Cleveland Clinic, Cleveland, OH, ¹²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ¹³Rheumatology, Duke University Medical Center, Durham, NC, ¹⁴Immune Tolerance Network, San Francisco, CA, ¹⁵Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁶Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ¹⁷Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹⁸Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Ocular involvement in ANCA-associated vasculitis (AAV) can cause substantial morbidity. We aimed to characterize patterns of ocular involvement in AAV and their response to…
Abstract Number: 1948 • 2016 ACR/ARHP Annual Meeting
Evaluation of Body Composition Parameters in Granulomatosis with Polyangiitis: Association of Fat Mass Parameters with Disease Activity and Inflammatory Markers
Mariana O Perez¹, Valeria F Caparbo², Mauricio Levy-Neto² and Rosa M R Pereira², ¹Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Granulomatosis with polyangiitis (GPA, Wegener´s) patients are more exposed to traditional cardiovascular risk factor, including obesity. In rheumatic diseases, inflammation has been associated with…
Abstract Number: 1949 • 2016 ACR/ARHP Annual Meeting
Presentation, Prognosis and Clinical-Pathological Correlations of Cutaneous Manifestations in ANCA-Associated Vasculitides
Laure Frumholtz¹, Sara Laurent², Olivier Aumaître³, Francois Maurier⁴, Guillaume Le Guenno⁵, Agnès Carlotti², Alexiane Dallot², Jean-Louis Kemeny⁶, Laurent Antunes⁷, Nicolas Froment⁷, Sylvie Fraitag⁸, Jonathan London⁹, Claire Le Jeunne¹⁰, Benoit Terris², Luc Mouthon¹⁰, Selim Aractingi¹¹, Loïc Guillevin¹⁰, Nicolas Dupin¹¹ and Benjamin Terrier¹², ¹Internal Medicine, Cochin Hospital, Paris, France, ²Pathology, Cochin Hospital, Paris, France, ³CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁴Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁵Internal Medicine department, Clermont-Ferrand, France, ⁶Pathology, CHU, Clermont-Ferrand, France, ⁷Pathology, CH, Metz, France, ⁸Pathology, Necker, Paris, France, ⁹INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹¹Dermatology, Cochin Hospital, Paris, France, ¹²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Cutaneous involvement is frequent during ANCA-associated vasculitis (AAV) and can reveal the disease. However, no large study on presentation and clinical-pathological correlations is available.…
Abstract Number: 1950 • 2016 ACR/ARHP Annual Meeting
ANCA-Associated Vasculitides and IgG4-Related Disease: An Overlapping Syndrome? a European Observational Study of 18 Patients
Francois-Xavier Danlos¹, Giovanni Maria Rossi², Daniel Blockmans³, Giacomo Emmi⁴, Andreas Kronbichler⁵, Stéphane Durupt⁶, Claire Maynard⁷, Luminita Luca⁸, Cyril Garrouste⁹, Bertrand Lioger¹⁰, Rachel Mourot¹¹, Robin Dhote¹², Jean-Benoit Arlet¹³, Thomas Hanslik¹⁴, Mikael Ebbo¹⁵, Agnès Carlotti¹⁶, Luc Mouthon¹⁷, Loïc Guillevin¹⁷, Augusto Vaglio¹⁸ and Benjamin Terrier¹⁹, ¹Internal Medicine, Cochin Hospital, Paris, France, ²Nephrology, Parma, Parma, Italy, ³General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁴Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁵Nephrology, Hospital, Innsbruck, Austria, ⁶Internal Medicine, CHU, Lyon, France, ⁷Internal Medicine, CH, Chambéry, France, ⁸Internal Medicine, CHU, Poitiers, France, ⁹Nephrology, CHU, Clermont-Ferrand, France, ¹⁰GICC UMR 7292, University François Rabelais, Tours, France, ¹¹Internal Medicine, CHU, Strasbourg, France, ¹²Service de médecine interne. Hôpital Avicenne, Paris, France, ¹³Service de médecine interne, Hopital Européen Georges Pompidou, Paris, France, ¹⁴Internal Medicine, CHU, Boulogne Billancourt, France, ¹⁵Internal Medicine, Aix-Marseille Université, AP-HM, Marseille, France, ¹⁶Pathology, Cochin Hospital, Paris, France, ¹⁷Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁸Nephrology, University Hospital of Parma, Parma, Italy, ¹⁹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Atypical manifestations have been described in patients with antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV), such as periaortic fibrosis, pachymeningitis and orbital mass. Because these…
Abstract Number: 1951 • 2016 ACR/ARHP Annual Meeting
Phenotypic and Functional Perturbations of Peripheral B and T Lymphocytes in Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Jonathan London^1,2,3, Nicolas Dumoitier¹, Jeremie Dion^1,4, Benjamin Chaigne^1,5, Sebastien Lofek¹, Pascal Cohen^2,3, Claire Le Jeunne³, Nadine Varin-Blank⁶, Loïc Guillevin^3,5, Benjamin Terrier^1,5,7, Luc Mouthon^1,3,5 and the French Vasculitis Study Group, ¹INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ²Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁴Internal medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁶UFR SMBH, INSERM, UMR978, Bobigny, France, ⁷Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are both anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitides (AAV), but differ in clinical presentation. Anti-myeloperoxydase (MPO)-ANCA were…
Abstract Number: 1952 • 2016 ACR/ARHP Annual Meeting
Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis
Judith Land¹, Lucas L. Lintermans¹, Coen A. Stegeman², Ernesto J. Muñoz-Elías³, Peter Heeringa⁴, Abraham Rutgers¹ and Wayel H. Abdulahad¹, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Kineta Inc, Seattle, WA, ⁴Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Granulomatosis with polyangiitis (GPA) patients are often treated with immunesuppressives or B cell depleting therapy. While B cells are involved in GPA pathogenesis as…
Abstract Number: 1953 • 2016 ACR/ARHP Annual Meeting
Management and Outcomes of ANCA-Associated Vasculitis in Unselected Cases within a Large Health Region of England
Fiona Pearce¹, Catherine McGrath², Ravinder Sandhu³, Jon Packham⁴, Karen Obrenovich⁵, Richard A. Watts⁶, Peter Lanyon⁷ and for the East Midlands, West Midlands and East of England regional audit groups, ¹Epidemiology and Public Health, University of Nottingham, Nottingham, United Kingdom, ²Department of Rheumatology, The Dudley Group NHS Foundation Trust, Dudley, United Kingdom, ³The Dudley Group NHS Foundation Trust, Dudley, Great Britain, ⁴University of Keele, Keele, United Kingdom, ⁵The Dudley Group NHS Foundation Trust, Dudley, United Kingdom, ⁶Rheumatology Department, Ipswich Hospital, Ipswich, Great Britain, ⁷Department of Rheumatology, Nottingham University Hospitals NHS trust, Nottingham, United Kingdom
Background/Purpose: Most data on management and outcomes of ANCA-associated vasculitis (AAV) come from highly selected populations in tertiary referral centres, or clinical trials. These results…
Abstract Number: 1954 • 2016 ACR/ARHP Annual Meeting
Clinical Features and Long Term Outcome of 105 Patients of Granulomatosis with Polyangiitis: A Single Centre Experience from North India
Aman Sharma¹, Shankar Naidu², Manish Rathi³, Benzeeta Pinto⁴, Kusum Sharma⁵, Varun Dhir⁶, Ritambhra Nada⁷, Ranjana Minz⁸ and Surjit Singh⁹, ¹Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²PGIMER, cHANDIGARH, India, ³Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁴PGIMER, CHANDIGARH, India, ⁵Department of Medical Microbiology,, PGIMER,, Chandigarh, India, ⁶Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁷Histopathology, Professor, Chandigarh, India, ⁸Department of Immunopathology,, PGIMER,, Chandigarh, India, ⁹Department of Internal Medicine,, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: The published Indian data on Granulomatosis with Polyangiitis (GPA) is sparse and only in the form of few small case series. The purpose of this study…
Abstract Number: 1955 • 2016 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months
Benjamin Terrier¹, Christian Pagnoux², Elodie Perrodeau³, Alexandre Karras⁴, Chahéra Khouatra⁵, Olivier Aumaître⁶, Pascal Cohen⁷, Francois Maurier⁸, Olivier Decaux⁹, Hélène Desmurs-Clavel¹⁰, Pierre Gobert¹¹, Thomas Quémeneur¹², Claire Blanchard-Delaunay¹³, Pascal Godmer¹⁴, Xavier Puéchal¹⁵, Luc Mouthon¹⁵, Philippe Ravaud¹⁶ and Loïc Guillevin¹⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁴Nephrology, HEGP, Paris, France, ⁵CHU Lyon, Lyon, France, ⁶CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁷Internal Medicine, Cochin Hospital, Paris, France, ⁸Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁹Department of Internal Medicine, Rennes University Hospital, Rennes, France, ¹⁰Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ¹¹Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹²Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ¹³Internal Medicine, Centre Hospitalier, Niort, France, ¹⁴CH Vannes, Vannes, France, ¹⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁶Hôpital Hôtel Dieu, Paris, France
Background/Purpose: The previously reported prospective, randomizedÐcontrolled MAINRITSAN trial compared rituximab (RTX) to azathioprine (AZA) for maintenance of ANCA-associated vasculitis (AAV) remissions obtained with a combined…
Abstract Number: 1956 • 2016 ACR/ARHP Annual Meeting
High Dose Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor Inhibitor Use Results in Less Radiographic Progression in Ankylosing Spondylitis – a Longitudinal Analysis
Lianne S. Gensler¹, John D. Reveille², MinJae Lee³, Thomas Learch⁴, Matthew Brown⁵, Mohammad H. Rahbar³, Michael Weisman⁶ and Michael Ward⁷, ¹Medicine/Rheumatology, UCSF, San Francisco, CA, ²Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ³Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁴Radiology, Cedars Sinai Medical Center, Los Angeles, CA, ⁵Queensland University of Technology, Brisbane, Australia, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷NIH/NIAMS, Bethesda, MD
Background/Purpose: Over the last decade, the disease modifying effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor inhibitors (TNFi) have resulted in conflicting studies. …
Abstract Number: 1957 • 2016 ACR/ARHP Annual Meeting
No Increased Risk of Chronic Kidney Disease with Allopurinol Use
Ana Beatriz Vargas-Santos¹, Christine Peloquin², Yuqing Zhang³ and Tuhina Neogi¹, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Chronic kidney disease (CKD) is a cause and consequence of hyperuricemia. While clinicians are often cautious about using allopurinol in patients with CKD, there…
Abstract Number: 1958 • 2016 ACR/ARHP Annual Meeting
Effect of Poverty Status in 2009, % of Years in Poverty Between 2003 and 2009, and Exiting Poverty Permanently By 2009 on SLE Damage in 2015
Edward H. Yelin¹, Jinoos Yazdany² and Laura Trupin³, ¹Medicine/Rheumatology, UC San Francisco, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose : The relationship between poverty and SLE damage has been observed in several cross-sectional studies. The aim of the present study was to use…
Abstract Number: 1959 • 2016 ACR/ARHP Annual Meeting
How Do Bone Marrow Lesions Cause Osteoarthritis Pain? a Structural and Functional Tissue-Based Study
Nidhi Sofat¹, Lena Assi², Anasuya Kuttapitiya³, Alan Boyde⁴, Vivian Ejindu⁵ and Christine Heron⁵, ¹Basic Medical Sciences, St. George's, University of London, London, United Kingdom, ²St George's University of London, Institute for Infection & Immunity, London, United Kingdom, ³St George's, University of London, Institute for Infection & Immunity, London, United Kingdom, ⁴Queen Mary University of London, London, United Kingdom, ⁵Department of Radiology, St George's Hospital, London, United Kingdom
Background/Purpose: Bone marrow lesions (BML) are well described in osteoarthritis (OA) and associate with pain, but little is known about histological and functional features of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].